NANOBIOTIX will receive $60M in near-term cash & operational support incl. $30M up front & ~$30M in regulatory & development support for the (NANORAY-312) study, ~$1.8B in milestones & an additional development & regulatory milestone of ~$650M for 5 new indications, ~$220M as per indication, $30 million in equity investments along with royalties
Janssen to get a license globally for the development & commercialization of NBTXR3 & will lead an initial P-II study of NBTXR3 for stage three lung cancer & also get the rights to control studies currently led by NANOBIOTIX
NANOBIOTIX will maintain operational control of (NANORAY-312) & other ongoing studies along with NBTXR3 manufacture, clinical supply, & initial commercial supply. NBTXR3 is being studied in multiple studies across solid tumor
Ref: Globenewswire | Image: Nanobiotix
Related News:- Nanobiotix Collaborates with Lianbio to Develop and Commercialize NBTXR3 in China and other Asian Countries
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
